MedX (MDX:TSXV) Telemedicine Platform For Skin Cancer Gets Record Order, Set To Generate Millions In 2020

MedX (MDX:TSXV) is the  "overnight 5-year success story" that most retail investors have never  heard about ... but that is all about to change in 2020, a year that is  set to dwarf the $860,000 in revenue MDX generated in 2019.

What do they do?  In layman's terms, they've combined their skin  cancer scanning device with proprietary software to create a  telemedicine platform focused on skin cancer.  In essence, you scan a  troubling spot on your body and within 72 hours you can have both a  prognosis and treatment completed - god forbid.

Sounds like a cool idea but does it work?  Glad you asked.  The  platform was proven through a proof-of-concept trial in Norway where 109  pharmacies captured 80,000 scans and found 860 cases of melanoma.

2020 is shaping up to be both the Company's best year ever and the beginning of something potentially great.  Why?

1.  MDX signed an exclusive distribution deal that led to the  Company receiving its biggest order in history - 500 units.  With much  more expected to come due to minimum annual sales requirements.

2.  MDX just did the same thing in Mexico on Monday.

Mike Druhan, Vice President of Corporate Development, believes more  countries are set to follow.  We'd love to tell you more but trust us  when we tell you that we've saved the best for the interview.

Telemedicine is going to be a monster, disruptive industry this  decade and MDX has the early upper hand in the world of skin cancer.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.